Related Experiment Video
Updated: Jun 26, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Bevacizumab treatment in multifocal lymphangioendotheliomatosis with thrombocytopenia
Ronald M Kline1, Laura Marcu Buck
1Pediatric Division, Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada 89109, USA. ronald.kline@usoncology.com
Abstract:
Multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT) is a rare disorder characterized by a proliferation of cutaneous and gastrointestinal (GI) lesions that have characteristics of both lymphatic and vascular lesions. Thrombocytopenia is associated with this syndrome and is thought to represent platelet destruction within the lesions. The natural history is one of multiple, life-threatening episodes of GI bleeding. We report the successful use of bevacizumab in this disease, an antibody to the vascular endothelial growth factor.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
